Armata Pharmaceuticals, Inc. (ARMP) Misses Q3 EPS by 60c

Armata Pharmaceuticals, Inc. (NYSE: ARMP) reported Q3 EPS of ($0.86), $0.60 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $950 thousand.

For earnings history and earnings-related data on Armata Pharmaceuticals, Inc. (ARMP) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• Citi maintains buy ratings on Argentina power firms amid sector shifts
• DA Davidson Reiterates Buy Rating on Jack Henry (JKHY)